A new cell therapy biotech emerges to find solid tumor-killing immune cells in patients' blood
A new autologous cell therapy maker is coming to the fore with $10 million to start.
Chicago-based CTRL Therapeutics hopes to expand beyond the current scope of cancers treated by existing cell therapies and also introduce a less complex process for patients and manufacturers.
CTRL is trying to build on another next-generation cell therapy method known as tumor infiltrating lymphocyte, or TIL, therapy. That approach, though, requires surgically removing cells from the patient’s tumor. Iovance Biotherapeutics, after years of delays, finished submitting its TIL therapy last month in the hopes of garnering the first such FDA approval. Meanwhile, another TIL player, Instil Bio, ended a trial and downsized in recent months.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.